Markets:

Overview

News

Currencies

International

Treasuries

Novartis AG Common Stock (NY:NVS)

131.19 +0.18 (+0.14%)

Official Closing Price Updated: 7:00 PM EST, Dec 10, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Novartis AG Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

39 40 Next >

Novartis AG-Sponsored ADR (NYSE:NVS): A Quality Dividend Stock with Strong Financials ↗

Today 4:11 EST

Novartis (NVS) offers a reliable 3.27% dividend yield, backed by strong profitability, a healthy balance sheet, and a history of consistent payouts.

Via Chartmill

Silver Shines as Global Tariff Storm Gathers: A Safe-Haven and Strategic Imperative in 2025

December 09, 2025

As global trade tensions escalate dramatically throughout late 2024 and 2025, marked by a surge in protectionist policies and tit-for-tat tariffs, silver has emerged as a dual-threat asset: a critical...

Via MarketMinute

Novartis' Investigational Drug Reports Longer Disease Control In Patients With Rare Blood Disorder ↗

December 09, 2025

Novartis reports Phase 3 results showing that combining ianalumab with eltrombopag significantly extends disease control and improves sustained platelet response in ITP patients.

Via Benzinga

Novartis Stock Softens Premarket Even As It Raises 2030 Outlook, Sales Guidance For Two Key Cancer Drugs ↗

November 20, 2025

Via Stocktwits

Big Pharma Layoff Wave Extends Into Next Year: UNH, Merck, BMS, Novartis File New WARN Notices ↗

November 20, 2025

Via Stocktwits

Topics Workforce

Novartis Opens New Manufacturing Facility In California In Bid To Increase US Presence ↗

November 10, 2025

Via Stocktwits

Can the Vanguard International High Dividend Yield Index Fund ETF Shares Outperform Again in 2026? ↗

December 07, 2025

This low-cost international dividend ETF nearly doubled the S&P 500's return in 2025 -- but replicating that performance will require the stars to align once more.

Via The Motley Fool

Topics ETFs Economy Stocks

Is Alnylam Pharmaceuticals a Millionaire Maker? ↗

December 07, 2025

This hot biotech stock could have a lot more room to run.

Via The Motley Fool

Global Prescription Drug Market Poised for Trillion-Dollar Surge by 2035

December 03, 2025

The global prescription drugs market is on the cusp of a significant expansion, with recent market reviews and forecasts projecting a robust growth trajectory through 2035. This anticipated surge,...

Via MarketMinute

Topics Artificial Intelligence Death Intellectual Property

Morgan Stanley Downgrades Regeneron (REGN) to Equal-Weight, Citing Fair Valuation and Pipeline Scrutiny

December 03, 2025

New York, NY – December 3, 2025 – In a significant move reverberating through the biotechnology sector, investment banking giant Morgan Stanley has downgraded Regeneron Pharmaceuticals (NASDAQ: REGN)...

Via MarketMinute

Topics Intellectual Property

Janux Therapeutics Stock Sinks 50% After Prostate Cancer Trial Triggers Target Cuts Across Wall Street — Retail Sees A FOMO-Fueled Rebound ↗

December 02, 2025

Janux shares plunged after the JANX007 trial update prompted widespread target cuts, even as retail traders framed the selloff as poised for a rebound.

Via Stocktwits

1 No-Brainer International Vanguard ETF to Buy Right Now for Less Than $100 ↗

November 29, 2025

A weakening dollar makes this ETF more appealing.

Via The Motley Fool

Topics Artificial Intelligence ETFs Economy

2 High-Yielding ETFs That Can Bankroll Your Retirement for Years ↗

November 29, 2025

These funds offer yields that are more than three times the S&P 500 average.

Via The Motley Fool

Topics ETFs Economy Retirement

Why Novartis Stock Topped the Market Today ↗

November 25, 2025

The company has a brand-new product to ship to pharmacies.

Via The Motley Fool

FDA OKs Novartis SMA Treatment As First Gene Therapy Option For Kids, Teens And Adults ↗

November 25, 2025

Novartis wins FDA approval for Itvisma, a one-time gene therapy offering broader SMA treatment with sustained motor function improvements.

Via Benzinga

Novartis Stock Rises Premarket After FDA Approves First Gene Therapy For Teens And Adults With Muscle-Weakening Disorder ↗

November 25, 2025

FDA cleared Itvisma as the first gene-replacement therapy available to people 2 and older with the rare muscle-weakening condition.

Via Stocktwits

NOVARTIS AG-SPONSORED ADR (NYSE:NVS): A Comprehensive Value Investment Analysis ↗

November 24, 2025

Novartis (NVS) appears undervalued with a low P/E ratio, strong profitability, and solid financial health, making it a compelling stock for value investors.

Via Chartmill

European Stocks Soar as Strong Earnings Quell 'AI Bubble' Fears

November 20, 2025

European equity markets have experienced a significant resurgence around November 20, 2025, with major indices climbing as robust company results, particularly from the technology sector, have...

Via MarketMinute

Topics Artificial Intelligence Economy Supply Chain

Novartis Projects Faster Growth Through 2030 After Raising Drug Forecasts ↗

November 20, 2025

Novartis raises long-term sales targets, boosts outlook for key medicines and outlines a pipeline strategy driving growth through 2030.

Via Benzinga

Is the Market Bullish or Bearish on Novartis AG? ↗

November 18, 2025

Via Benzinga

Is AI The Key To Beating Cancer? Why Pharma Stocks Are Soaring ↗

November 17, 2025

AI breakthroughs in pharma are pushing Eli Lilly and healthcare stocks higher—and may soon reshape how we fight cancer.

Via Benzinga

Topics Artificial Intelligence

Novartis AG-Sponsored ADR (NYSE:NVS) Presents a Strong Case for Dividend Investors ↗

November 17, 2025

Novartis (NVS) offers a strong 3.31% dividend yield with a history of reliable payouts and growth, backed by excellent profitability and financial health.

Via Chartmill

Trump Unveils $200 Billion Trade Deal With Switzerland And Liechtenstein To Cull $38.5 Billion US Goods Deficit By 2028 ↗

November 15, 2025

President Donald Trump announced a framework for a trade deal with Switzerland and Liechtenstein on Friday.

Via Benzinga

Topics Government

AI Revolutionizes Drug Shelf-Life: Optimized Stability Models Promise Safer, More Effective Medicines

November 14, 2025

The pharmaceutical industry is on the cusp of a profound transformation, driven by the integration of data science and Artificial Intelligence (AI) into drug formulation stability models. This...

Via TokenRing AI

Topics Artificial Intelligence Economy Product Recall

Biopharma Boom: M&A Frenzy, AI Revolution, and GLP-1 Gold Rush Drive Robust Growth in 2025

November 14, 2025

The pharmaceutical and biotechnology sectors are experiencing a period of significant dynamism and robust growth as of November 2025, fueled by a confluence of scientific advancements, a resurgence in...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

AI Revolutionizes Cardiovascular Clinical Trials: A Leap Towards Cheaper, Faster Drug Development

November 13, 2025

San Francisco, CA – November 13, 2025 – Artificial Intelligence (AI) has achieved a pivotal breakthrough in the medical field, successfully adjudicating clinical events in cardiovascular trials. This...

Via TokenRing AI

Topics Artificial Intelligence

Novartis' Investigational Medicine Shows Potent Activity Against Drug-Resistant Malaria Strains ↗

November 13, 2025

Novartis' GanLum met key Phase 3 goals, showing strong efficacy and safety in malaria patients, including against resistant parasite strains.

Via Benzinga

Eledon Pharmaceuticals Stock Plunges Following $50 Million Public Offering

November 12, 2025

Irvine, CA – November 12, 2025 – Eledon Pharmaceuticals (NASDAQ: ELDN) witnessed a significant decline in its stock value today, plummeting by 17.8% in premarket trading. This sharp drop comes on the...

Via MarketMinute

Topics Initial Public Offering Intellectual Property Regulatory Compliance

AI’s Next Frontier: Key Stocks to Watch Amidst Market Shifts and Technological Leaps

November 10, 2025

The artificial intelligence (AI) sector is currently navigating a period of unprecedented dynamism, characterized by explosive technological advancements, massive capital inflows, and a palpable...

Via TokenRing AI

Topics Artificial Intelligence

AI Achieves Atomic Precision in Antibody Design: A New Era for Drug Discovery Dawns

November 05, 2025

Seattle, WA – November 5, 2025 – In a monumental leap for biotechnology and artificial intelligence, Nobel Laureate David Baker’s lab at the University of Washington’s Institute for Protein Design...

Via TokenRing AI

Topics Artificial Intelligence Intellectual Property

< Previous 1 2 3 4 5 6 7 8 9

...

39 40 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.